Anti-inflammatory therapies in sepsis and septic shock (Q34074976)

30 July 2017

1 reference

title

Anti-inflammatory therapies in sepsis and septic shock (English)

1 reference

30 July 2017

0 references

1 reference

Freeman BD

1

1 reference

30 July 2017

Natanson C

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

1651-1663

1 reference

New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

The sirens' songs of confirmatory sepsis trials: selection bias and sampling error.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

PROTECTION OF ADRENALECTOMIZED ANIMALS AGAINST BACTERIAL INTOXICATION BY AN EXTRACT OF THE ADRENAL CORTEX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Experimental pneumococcal and staphylococcal sepsis: effects of hydrocortisone and phenoxybenzamine upon mortality rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Increased survival with methylprednisolone treatment in canine endotoxin shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Steroid controversy in sepsis and septic shock: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Cortisol response to corticotropin and survival in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Reversal of late septic shock with supraphysiologic doses of hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1651

10.1517/13543784.9.7.1651

21 January 2018

Identifiers

DOI

1 reference

release_apumozvwabgijibo65azxqis4i

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/apumozvwabgijibo65azxqis4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference